Cargando…

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab

OBJECTIVE: To determine the influence of immunoglobulins (Ig) level on the rate of infections in people with multiple sclerosis (pwMS) treated with ocrelizumab. METHODS: We enrolled 109 consecutive pwMS treated with ocrelizumab with a mean follow-up of 2.69±0.56 (1.36-4.27) years. We have retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habek, Mario, Piskač, Dominik, Gabelić, Tereza, Barun, Barbara, Adamec, Ivan, Krbot Skorić, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994678/ https://www.ncbi.nlm.nih.gov/pubmed/35429819 http://dx.doi.org/10.1016/j.msard.2022.103798

Ejemplares similares

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness
por: Barun, Barbara, et al.
Publicado: (2021)

Evolution of tongue somatosensory evoked potentials in people with multiple sclerosis
por: Krbot Skorić, Magdalena, et al.
Publicado: (2020)

COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population
por: Mayer, Dijana, et al.
Publicado: (2023)

Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies
por: Habek, Mario, et al.
Publicado: (2022)

Tongue somatosensory evoked potentials reflect midbrain involvement in patients with clinically isolated syndrome
por: Krbot Skorić, Magdalena, et al.
Publicado: (2016)

Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
por: Habek, Mario, et al.
Publicado: (2021)

Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society
por: Habek, Mario, et al.
Publicado: (2022)

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022)

Effect of Food Intake on Hemodynamic Parameters during the Tilt-Table Test in Patients with Postural Orthostatic Tachycardia Syndrome
por: Habek, Mario, et al.
Publicado: (2019)

Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
por: Adamec, Ivan, et al.
Publicado: (2022)

Validation and cross-cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosis
por: Drulović, Jelena, et al.
Publicado: (2017)

The incidence of postural orthostatic tachycardia syndrome in the population of Zagreb, Croatia
por: Adamec, Ivan, et al.
Publicado: (2020)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

The Relationship between Autonomic Regulation of Cardiovascular Function and Body Composition
por: Smoljo, Tomislav, et al.
Publicado: (2020)

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
por: Conte, William L
Publicado: (2020)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

The impact of the comorbid seizure/epilepsy on the health related quality of life in people with multiple sclerosis: an international multicentric study
por: Drulovic, Jelena, et al.
Publicado: (2023)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
por: Feng, Jenny J, et al.
Publicado: (2017)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Viral pericarditis following ocrelizumab in a multiple sclerosis patient
por: Miele, Giuseppina, et al.
Publicado: (2023)

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
por: Seery, Nabil, et al.
Publicado: (2021)

Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series
por: De Mercanti, Stefania F., et al.
Publicado: (2021)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4n5arr90ck2c8lpu0tr0ocj5np